It has two major catalysts. 1. It has a FDA decision date of May 4th for it's inhaled antipsychotic drug Adasuve (Staccato Loxipine). Loxapine is already available in the US, this would be an inhaled version.
2. They have a partner Grupo Ferrer that will distribute the drug in Europe, Latin America, and Russia and instead of milestone payments to Alexa, they have agreed to purchase 2.42 million common shares of ALXA at a price of 1.24, 100% gain from current levels upon Alexa's request, and another 8 million at a premium instead of future milestone payments.
This has a potential if approved of possibly a 300-400% gain in the next month from these levels IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.